Predict your next investment

HEALTHCARE | Drug Development
bacbv.com

See what CB Insights has to offer

Competitors

14

Business Relationships

4

BAC Competitors & Alternatives

14 Competitors

BAC has 14 competitors. BAC's competitors are Sirion Biotech, KIYATEC, HTG Molecular Diagnostics, WaferGen Bio-systems, ZyGEM and more.

Latest Funding

Companies

Investment Stage

Total Funding

Mosaic
The Mosaic Score is an algorithm that measures the overall financial health and market potential of private companies.

Location

6/22/2021

Acquired

Germany

4/30/2021

Series C

$11.56M

South Carolina

4/14/2020

Loan

$71.28M

Arizona

5/13/2016

Acq - P2P

California

4/14/2016

Asset Sale

New Zealand

2/4/2014

Life Technologies Corporation

Acq - P2P

California

9/8/2011

Caliper Life Sciences

Acq - P2P

$37.09M

Massachusetts

2/23/2010

TwoF

Series C

$5.74M

California

10/1/2009

Alpha Innotech

Acquired

$8.88M

California

8/14/2009

Solidus Biosciences

Grant

$0.8M

New York

Latest Funding

6/22/2021

4/30/2021

4/14/2020

5/13/2016

4/14/2016

2/4/2014

9/8/2011

2/23/2010

10/1/2009

8/14/2009

Companies

Life Technologies Corporation

Caliper Life Sciences

TwoF

Alpha Innotech

Solidus Biosciences

Investment Stage

Acquired

Series C

Loan

Acq - P2P

Asset Sale

Acq - P2P

Acq - P2P

Series C

Acquired

Grant

Total Funding

$11.56M

$71.28M

$37.09M

$5.74M

$8.88M

$0.8M

Mosaic

Location

Germany

South Carolina

Arizona

California

New Zealand

California

Massachusetts

California

California

New York

BAC Partners & Customers

4 Partners and customers

BAC has 4 strategic partners and customers. BAC recently partnered with Octapharma on August 8, 2017.

Date

Type

Business Partner

Country

News Snippet

Sources

8/17/2017

Partner

Octapharma

Switzerland

Octapharma Extends Use of BAC Technology for Manufacture of G-CSF Custom Ligand

This license follows success in an earlier feasibility study program in which BAC discovered and developed the anti-G-CSF ligand in close collaboration with Octapharma .

2

8/17/2010

Licensee

Octapharma

Switzerland

Subscribe to see more

Subscribe to see more

10

11/2/2009

Partner

Octapharma

Switzerland

Subscribe to see more

Subscribe to see more

10

11/3/2008

Partner

General Electric

United States

Subscribe to see more

Subscribe to see more

10

Date

8/17/2017

8/17/2010

11/2/2009

11/3/2008

Type

Partner

Licensee

Partner

Partner

Business Partner

Octapharma

Octapharma

Octapharma

General Electric

Country

Switzerland

Switzerland

Switzerland

United States

News Snippet

Octapharma Extends Use of BAC Technology for Manufacture of G-CSF Custom Ligand

This license follows success in an earlier feasibility study program in which BAC discovered and developed the anti-G-CSF ligand in close collaboration with Octapharma .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

2

10

10

10

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.